Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer
| Autor: | Hampig Raphael Kourie, Philippe Aftimos, Martine Piccart, Nicolas Mavroudakis |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
congenital hereditary and neonatal diseases and abnormalities medicine.medical_specialty Peripheral neuropathy Case Report Docetaxel 03 medical and health sciences Breast cancer 0302 clinical medicine Trastuzumab Internal medicine Neurotoxicity medicine Charcot-Marie-Tooth IA business.industry Cancer Généralités Peroneal muscular atrophy medicine.disease Metastatic breast cancer nervous system diseases 030220 oncology & carcinogenesis Pertuzumab business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | World Journal of Clinical Oncology World Journal of Clinical Oncology, 8 (5 |
| ISSN: | 2218-4333 |
| DOI: | 10.5306/wjco.v8.i5.425 |
| Popis: | Charcot-Marie-Tooth (CMT) neuropathy is the most common hereditary cause of neuropathy. Diagnosis is usually not made during the childhood but in adolescence or late adulthood. It is reported in the literature that some neurotoxic chemotherapeutical agents can reveal an asymptomatic CMT IA hereditary neuropathy. To our knowledge, we report here the first case of CMT IA revealed in a 55-year-old woman after the administration of docetaxel/trastuzumab/pertuzumab for metastatic breast cancer. This case stresses again the necessity to obtain a complete personal and familial anamnesis and to perform a neurologic examination before the administration of neurotoxic chemotherapeutical agents to prevent the clinical expression of these hereditary neuropathies. SCOPUS: ar.j info:eu-repo/semantics/published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|